TrialOncotarget2016

Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China.

Qingyuan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.